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Synthetic biology may help us create artificial life, but how should we patent it? Wellcome Images  
With promises of improved medical treatments, greener energy and even artificial 
life, the field of synthetic biology has captured the public imagination and attracted 
significant government and commercial investment.  
This excitement reached a crescendo on 21 May 2010, when scientists at the J 
Craig Venter Institute in the United States announced that they had made a “self-
replicating synthetic bacterial cell”. This was the first living cell to have an entirely 
human-made genome, which means that all of the cell’s characteristics were 
controlled by a DNA sequence designed by scientists.  
This achievement in biological engineering was made possible by combining 
molecular biotechnology, gene synthesis technology and information technology. 
Possibilities of synthetic biology 
In his autobiography, A Life Decoded, J. Craig Venter contends that synthetic 
biology has the potential to address concerns about energy security, climate change 
and sustainable development: “My company, Synthetic Genomics Inc., is already 
trying to turn an organism into a biofactory that could make clean hydrogen fuel 
from sunlight and water or soak up more carbon dioxide.” 
He elaborated on his long-term scientific aspirations: “From there I want to take us 
far from shore into unknown waters, to a new phase of evolution, to the day when 
one DNA-based species can sit down at a computer to design another.” 
Venter maintained: “I plan to show that we understand the software of life by 
creating true artificial life”. 
Another leading researcher, Jay D. Keasling, is confident that the field of synthetic 
biology can increase access to essential medicines – particularly to provide 
protection against malaria.  
However, civil society groups and technology activists have raised concerns about 
the risks synthetic biology may pose to security, public health and the environment. 
The ETC Group, for instance, is concerned that organisms made with synthetic 
biology (such as engineered bacteria) could be released into the environment, with 
unknown effects. They’re also concerned about potential weaponisation of synthetic 
biology.  
Synthetic biology could be used to make clean hydrogen fuel from sunlight and water. Images by John 'K'  
Patentability 
There has been much controversy over the application of patent law to emerging 
technologies, with large legal battles over the patentability of information technology 
and business methods, genetic testing, medical information, and stem cell research. 
The field of synthetic biology also poses a number of challenges for patent law and 
public policy. One of the most important questions patent experts (such as 
Professor Graham Dutfield) are asking is whether synthetic biology is too different 
from previous biotechnologies to apply existing objections to the patenting of living 
things.  
In addition to considering patentability of synthetic biology, patent offices and 
courts will have to consider the novelty, inventiveness and utility of the claimed 
inventions and scope of the claims, in light of the scientific knowledge in this field.  
In the United States, patent applications for synthetic biology have fallen into two 
broad categories: 
1) biological tools, methods and products. 
2) computer programs. This includes software for design of biological devices and 
programs for analysis of biochemical activity within cells.  
Some US patent applications have focused on the construction of a synthetic cell. 
Scientists at the J Craig Venter Institute, for example, have filed applications for 
patents on a minimal bacterial genome, a synthetic genome and a method of 
installing a genome into a cell. 
Other US patent applications have involved the creation of useful biological 
products from cells, such as Jay D. Keasling and colleagues’ production of a 
malaria drug precursor in a genetically modified cell. 
There are also patent applications for various methods of biofuel production. 
Civil society groups are concerned about the risks of bioterrorism. Flickr/rmdey2000  
Law reform 
US President Barack Obama’s Presidential Commission for the Study of Bioethical 
Issues recommended that synthetic biology be regulated using the principles of 
public beneficence, responsible stewardship, intellectual freedom and responsibility, 
democratic deliberation and justice and fairness. 
The Commission was, however, hopeful that synthetic biology could “be developed 
in an ethically responsible manner”.  
But intellectual property expert Arti K. Rai has concerns that, as patent thickets 
have been a problem in the information technology and biotechnology sector, this 
could also slow the progress of synthetic biology research. 
To counter this risk, some scientists and researchers have called for the 
introduction of a broad defence of experimental use, under patent law, to protect 
them from the threat of patent litigation. 
The US-based group of scientists, BioBricks Foundation, already promotes open 
innovation in this field and have created a space to share their own research, right 
from the establishment of a new field. 
Sharing of information and resources in synthetic biology research is facilitated by 
the Registry of Standard Biological Parts, which is supported by a culture of sharing 
in the synthetic biology community. 
Somewhat more radically, biopunks – do-it-yourself biologists – question the use of 
intellectual property rights altogether in the field of synthetic biology. The 
international group of do-it-yourself biologists, known as DIYbio, has groups in North 
America, Europe and Asia, and individual members in many countries including 
Australia. 
In his book, Biopunk, Marcus Wohlsen explains that in the US he’s observed, “An 
intellectual property system designed to spur innovation by allowing inventors to 
profit off their inventions has become in biopunks’ eyes a high-stakes game of low-
stakes progress.” 
The emerging field of synthetic biology is ripe for law review and reform, both 
overseas and at home in Australia. We’re seeing a proliferation of patents in this 
field, with the potential for significant impact on health, the environment and the 
economy.  
If governments are serious about the progress of biological research, they will have 
to consider the implications of patenting and licensing of synthetic biology. 
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